Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

817
Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
817
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.2K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Target Trial Emulation of 6-Month Weight Change after Endoscopic Sleeve Gastroplasty and Sleeve Gastrectomy: A Retrospective Cohort Study.

Journal of the American College of Surgeons·2026
Same author

1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.

The lancet. Diabetes & endocrinology·2026
Same author

Cyclin D1 regulates the hepatic response to feeding: Evidence for non-cell cycle roles in the liver.

bioRxiv : the preprint server for biology·2026
Same author

Ectopic Adrenocorticotropic Hormone Syndrome Secondary to Pulmonary Neuroendocrine Tumor: Medical Stabilization Enables Serial Imaging and Localization.

AACE endocrinology and diabetes·2026
Same author

Sepsis After Elective Aortic Root Replacement: An Analysis Using the National Inpatient Sample.

The Journal of surgical research·2026
Same author

Integrated glucagon model for estimation of α-cell responsivity to glucose and amino acids during graded glucose infusion.

American journal of physiology. Endocrinology and metabolism·2026

Related Experiment Video

Updated: Jan 17, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.2K

Primary Aldosteronism Surgery Outcomes Under Current Blood Pressure Guidelines.

Kidmealem Zekarias1, Jacob Kohlenberg1, Sayeed Ikramuddin2

  • 1Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
|September 13, 2025
PubMed
Summary

Adrenalectomy for primary aldosteronism (PA) shows 90% success in improving blood pressure (BP) or reducing medications. Complete BP normalization (16.5%) is lower than historical rates due to stricter BP guidelines.

Keywords:
adrenalectomyblood pressureclinical outcomesprimary aldosteronismsurgical outcomes

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

682
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.0K

Related Experiment Videos

Last Updated: Jan 17, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.2K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

682
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.0K

Area of Science:

  • Endocrinology
  • Surgical Oncology
  • Hypertension Management

Background:

  • Historical studies reported 37% complete clinical success after adrenalectomy for primary aldosteronism (PA) using a blood pressure (BP) threshold of <140/90 mmHg.
  • Current hypertension guidelines utilize a stricter BP threshold of <130/80 mmHg.

Purpose of the Study:

  • To evaluate clinical outcomes following adrenalectomy for PA using current BP guidelines.
  • To compare success rates with historical data based on older BP thresholds.

Main Methods:

  • Retrospective cohort study of 1079 adult patients undergoing adrenalectomy for PA (2013-2024).
  • Inclusion criteria: preoperative plasma aldosterone, ambulatory BP measurements pre- and post-adrenalectomy (6-18 months).
  • Exclusion: patients with pre-adrenalectomy BP < 130/80 mmHg without antihypertensive therapy.

Main Results:

  • Complete clinical success (BP < 130/80 mmHg without medications) was 16.5%.
  • Partial clinical success (improved BP control and/or reduced medications) was 73.5%.
  • Combined complete and partial success was 90%. Predictors of absent complete success included more preoperative antihypertensive medications, higher social vulnerability, and higher baseline BP.

Conclusions:

  • Adrenalectomy for PA yields meaningful clinical outcomes, with 90% achieving complete or partial success under current BP guidelines.
  • Complete clinical success rates are lower than previously reported due to the application of stricter BP targets.